Iovance raises 2026 revenue guidance to $410M-$420M

Iovance Biotherapeutics (NASDAQ: IOVA) raised its full-year 2026 total revenue guidance to a range of $410 million to $420 million, up from a prior range of $350 million to $370 million, according to a company statement.

The midpoint of the new range represents an increase of $55 million, or approximately 15%, over the previous guidance and implies nearly 60% annual growth in total revenue. The company attributed the revision to demand for Amtagvi (lifileucel) and Proleukin in the U.S. market.

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer, said: "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint. Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues."

Iovance reported record second quarter 2026 total product revenue of $99.3 million. The company said its authorized treatment center network has grown to approximately 100 centers and remains on track for expansion to at least 110 centers by year-end 2026.

The company expects to report third quarter 2026 financial results in early November 2026.

You May Also Be Interested In

• Pinnacle Financial Partners (PNFP) Tops Q3 EPS by 7c
• Integra LifeSciences (IART) PT Lowered to $14 at Citi
• S&P lowers Lamb Weston rating to ’BB’ with stable outlook amid elevated debt